Sweden's Wilson Therapeutics AB said that the first patient in a single pivotal trial of its copper-protein-binding agent for the rare copper-excess condition, Wilson disease, is expected to be enrolled in early 2018. Data from the study is anticipated to follow in the second half of 2019.